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Phenotypic and molecular analyses of
primary lateral sclerosis
ABSTRACT
Objective: To understand phenotypic and molecular characteristics of patients with clinically
“definite” primary lateral sclerosis (PLS) in a prospective study.
Methods: Six sites enrolled 41 patients who had pure upper motor neuron dysfunction, bulbar
symptoms, a normal EMG done within 12 months of enrollment, and onset of symptoms$5 years
before enrollment. For phenotypic analyses, 27 demographic, clinical, and cognitive variables
were analyzed using the k-means clustering method. For molecular studies, 34 available DNA
samples were tested for the C9ORF72 expansion, and exome sequencing was performed to
exclude other neurologic diseases with known genetic cause.
Results: K-means clustering using the 25 patients with complete datasets suggested that patients
with PLS can be classified into 2 groups based on clinical variables, namely dysphagia, objective bulbar
signs, and urinary urgency. Secondary analyses performed in all 41 patients and including only varia-
bles with complete data corroborated the results from the primary analysis. We found no evidence that
neurocognitive variables are important in classifying patients with PLS. Molecular studies identified
C9ORF72 expansion in one patient. Well-characterized pathogenic mutations were identified in
SPG7, DCTN1, and PARK2. Most cases showed no known relevant mutations.
Conclusions: Cluster analyses based on clinical variables indicated at least 2 subgroups of clini-
cally “definite” PLS. Molecular analyses further identified 4 cases with mutations associated with
amyotrophic lateral sclerosis, Parkinson disease, and possibly hereditary spastic paraplegia. Phe-
notypic and molecular characterization is the first step in investigating biological clues toward the
definition of PLS. Further studies with larger numbers of patients are essential. Neurol Genet
2015;1:e3; doi: 10.1212/01.NXG.0000464294.88607.dd
GLOSSARY
ALS 5 amyotrophic lateral sclerosis; ALS-CBS 5 Amyotrophic Lateral Sclerosis-Cognitive Behavioral Screen; COWAT 5
Controlled Oral Word Association Test; HSP5 hereditary spastic paraplegia; IRB5 Institutional Review Board; LMN5 lower
motor neuron; LPGM 5 Laboratory of Personalized Genomic Medicine; MND 5 motor neuron disease; PD 5 Parkinson
disease; PLS 5 primary lateral sclerosis; SNP 5 single nucleotide polymorphism; UMN 5 upper motor neuron.
Primary lateral sclerosis (PLS) is considered the rarest motor neuron disease (MND). It is clin-
ically characterized by isolated pure upper motor neuron (UMN) dysfunction. Thus, the absence
of lower motor neuron (LMN) involvement distinguishes PLS from amyotrophic lateral sclerosis
(ALS).1 The diagnosis of PLS is also based on excluding all definable diseases, such as multiple
sclerosis, myelopathy, metabolic diseases, and hereditary spastic paraplegia (HSP). In addition,
after a few years of observation, some patients with suspected PLS develop features of LMN
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dysfunction.2 Consequently, the diagnostic cri-
teria for PLS have been extended from the orig-
inally recommended 3 years without LMN
involvement to 4 years.3–5 Although patients
with PLS have markedly impaired motor func-
tion, PLS, unlike ALS, is not life-threatening.
PLS is suspected to be a heterogeneous dis-
ease.6,7 Because of its rarity, no prospective
studies have analyzed the clinical and molecu-
lar characteristics of PLS. However, such inves-
tigations are an essential first step to clearly
defining PLS and understanding the mecha-
nisms underlying the disease. Here, we report
novel analyses of the clinical phenotype and
genetic markers of PLS.
METHODS Standard protocol approvals, registrations,
and patient consents. The study protocol was approved by the
Institutional Review Board (IRB) of Columbia University (Proto-
col Numbers: AAAE1115 and AAAE4850) and the individual
IRBs of all participating sites.
Eligible patients were prospectively enrolled in this study,
which is a parallel study to ALS Multicenter Cohort Study of
Oxidative Stress (ALS COSMOS) (NIEHS, R01ES016348).
These 2 studies are nearly identical in structure and methodol-
ogy,6 except for eligibility criteria, follow-up visit frequency,
and number of participating sites.8
We defined clinically “definite” PLS when patients had (1) pure
UMN dysfunction for at least 5 years following symptom onset based
on subjective functional impairment2,3; (2) a normal EMG done
within 12 months of enrollment (minimum changes in only one
muscle were permitted)2,4; and (3) normal brain and spinal cord
neuroimaging with allowance for increased signal intensity in the
pyramidal tracts at the posterior internal capsules.9 Exclusion criteria
included patients in whom only the legs were affected, patients with
knownHSP, patients with a history ofMND in immediate family, or
those with other active neurologic and unstable medical diseases. The
absence of bulbar symptoms, such as dysarthria, dysphagia, or pseu-
dobulbar affect, although preferred, was not exclusionary.10
Biospecimens (blood, DNA, urine, and skin biopsies) were
collected, processed, and stored using appropriate methods.
The patients had extensive clinical examinations and cognitive
testing and had well-validated structured interviews as fully
described in ALS COSMOS.8
Phenotype cluster analyses. We collected data on 27 demo-
graphic and clinical variables for all 41 enrolled patients (table e-1 at
Neurology.org/ng). Primary analyses were conducted on the 25
patients with complete data; secondary analyses were conducted on
all 41 (table 1). Of the 27 potential clinical indicators, 5 (memory
impairment, car sickness, stuttering, difficulty spelling, and
predominantly unilateral symptoms) were present in no more
than 1 patient and therefore excluded from the analysis. Verbal
fluency was measured with the Written Verbal Fluency Test or
the Controlled Oral Word Association Test (COWAT) with F,
A, and S, which consisted of a combination of scores from the 3
subscales. Clinical verbal impairment was defined as either a Fluency
Test index score of at least 19 or a COWAT score at least 2 SDs
below the mean, adjusted for sex, age, and education level.11 Finally,
before conducting the cluster analysis, we standardized all variables,
continuous and binary, to a mean of 0 and an SD of 1 to ensure that
they had equal weight in the analysis.12 A sensitivity analysis in
which we scaled only the continuous variables and left the binary
variables as 0 or 1 showed no meaningful difference.
In a secondary analysis, we restricted the variables to those with
data available from all 41 patients, i.e., age, sex, disease duration, and
the 15 binary clinical variables. A cluster analysis was performed fol-
lowing the method described above. Data analyses were conducted
using SAS version 9.2 (SAS Institute, Cary, NC) and R version 3.0.1.
K-means clustering. In preliminary analyses, we examined the
plot of the within-groups sum of squares over a range of 2–15
possible clusters. Because we did not observe a “bend” in the plot
(indicating the optimal number of clusters) and this was an
exploratory analysis, we opted for 2 clusters in order to be
conservative and for ease of interpretation (figure 1).
We identified the 2 clusters using k-means with Euclidean
distance. Variables associated with the clustering were identified
in 2 steps. First, a model-building strategy using least absolute
shrinkage and selection operator (Lasso) identified potentially
important variables.13 These were included in a logistic regression
model. A Wald test for significance of parameters in the logistic
model was used to identify important clustering variables.
Genetic analysis. All testing on the available 34 patient samples
was performed in the Laboratory of Personalized Genomic Med-
icine (LPGM) at Columbia University.
C9ORF72 expansion testing. The presence of expanded re-
peats was determined using the method of Renton et al.14
Sequencing and bioinformatics. Sequence capture for high-
throughput sequencing was performed using Illumina TruSeq
exome capture reagents, and 100-bp paired-end sequencing was
performed on an Illumina HiSeq 2500 sequencer. Next-generation
sequencing data were mapped and variants were called using
NextGENe (SoftGenetics, State College, PA).15 Variant filtering and
comparative analysis were performed using the single nucleotide
polymorphism (SNP) catcher software developed by the LPGM.
This software relies on allele frequency and functional prediction
data from multiple publicly available databases, including ClinVar,16
1000 Genomes Project,17 Exome Variant Server,18 and MSV3D.19,20
Pathogenic mutations were confirmed by Sanger sequencing.
RESULTS All 41 patients had clinically typical PLS.
Six patients had no dysarthria or dysphagia, and
another 6 had the minimum EMG changes that were
permitted for enrollment (table e-1). All patients were
alive at the time of report, except 3 who died unexpect-
edly (patient 7 had a sudden death during sleep, patient
11 had a fall resulting in death, and patient 12 had
sepsis resulting in respiratory and cardiac failure).
Patient 4 had abnormal CSF (protein of 118 mg/dL
and 8 cells) due to a traumatic spinal tap.
Table 1 compares sociodemographic, clinical, and
cognitive variables between all patients (n 5 41) and
those patients with complete data (n 5 25). Gener-
ally, the data were similar across the 2 datasets, with a
slightly lower percentage of women and patients with
dysarthria, dysphagia, and objective bulbar signs in
patients with complete data.
Using Euclidean distance measures, we con-
structed a dendrogram to visualize the similarities in
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patients with complete data (figure 2). The first
branch separated 1 patient (case ID 7), leaving 24.
The second branch separated 6 patients, with 18 re-
maining. The resulting 2 clusters differentiated the 6
patients separated in the second step from the remain-
ing patients (i.e., case ID 7 was grouped with the 18
for a total of 19 patients in that cluster).
The Lasso model selected 6 of the 19 variables
associated with the cluster groupings: dysarthria, dys-
phagia, objective bulbar signs, urinary urgency,
weight loss, and sensory impairment, the presence
of which characterized the smaller cluster of 6 pa-
tients. Some of these clinical features were also
present in other patients. None of these 6 variables
was statistically significant in a joint logistic regression
model, which predicted cluster membership. How-
ever, in individual logistic regression models, dyspha-
gia (p5 0.01), objective bulbar signs (p5 0.01), and
urinary urgency (p 5 0.002) were associated with
cluster membership. The modeling step was not
based on an a priori specification of clustering varia-
bles and was exploratory in nature; therefore, the
p values should be interpreted cautiously.
Secondary analyses. Using all 41 patients, the plot of
the within-groups sum of squares by number of
clusters was similar to the curve found in the
primary analysis, without an obvious bend. We
again proceeded with the assumption of 2 clusters
for ease of interpretation. Similar to the primary
analysis, the Lasso model selected 7 of the 18
variables associated with the grouping: dysarthria,
dysphagia, objective bulbar signs, minimum EMG
changes, urinary urgency, weight loss, and female
sex. Of these 7 variables, none were associated with
cluster membership in a joint logistic regression
model. However, in individual logistic regression
models, dysphagia (p 5 0.004), objective bulbar
signs (p , 0.001), urinary urgency (p , 0.001), and
female sex (p 5 0.02) were associated with cluster
membership. With the exception of sex, the results
confirmed the primary analysis. Finally, we tested for
cluster differences in all the cognitive variables that
were not included in the k-means clustering and
none differed across the 2 groups.
We repeated the analyses for the 37 patients with
complete data for the Amyotrophic Lateral Sclerosis-
Cognitive Behavioral Screen (ALS-CBS) variables.
The plot of the within-groups sum of squares by
number of clusters was similar to that shown in figure
1. We proceeded assuming 2 clusters. The Lasso
model selected 9 of the 18 variables associated with
the grouping: age, disease duration at baseline, dysar-
thria, dysphagia, objective bulbar signs, minimum
EMG changes, urinary urgency, sensory impairment,
and female sex. Of these 9 variables, none were asso-
ciated with cluster membership in a joint logistic
model. However, in individual logistic regression
models, dysphagia (p5 0.009), objective bulbar signs
(p, 0.001), urinary urgency (p5 0.004), and female
sex (p 5 0.009) were associated with cluster mem-
bership. The final analysis used patients with no miss-
ing values on the ALS-CBS cognitive and behavior
scales. Results (not shown) were similar to those in
the primary analysis.
Exome sequencing. Table e-1 lists the mutations de-
tected by C9ORF72 expansion testing and exome
sequencing in genes associated with HSP, familial
Table 1 Sociodemographic, clinical, and cognitive data for patients with PLS
Characteristic All patients (N 5 41)
Patients with complete
data (N 5 25)
Demographic variables
Age, y 60 (9.1) 60 (8.0)
Disease duration at baseline, y 7.4 (2.0) 7.1 (2.1)
Sex, % female 46 40
Clinical signs and evaluations, %
Dysarthria 83 76
Dysphagia 46 36
Objective bulbar signs 44 36
Minimum EMG changes 15 16
Urinary urgency 39 36
Bowel urgency 5 4
Weight loss 7 12
Personality/cognitive changes 10 4
Sensory impairment 12 16
No SSEP from legs 2 4
Cognitive/behavioral test scores
Mini-Mental State Examination 28.8 (1.6) 28.6 (1.8)
N 5 38a
ALS-CBS cognitive 14.4 (2.9) 14.1 (3.1)
N 5 37a
ALS-CBS behavioral 9.6 (8.4) 9.0 (8.0)
N 5 32a
Verbal impairment, %b 85 80
CNS-LS 15.3 (5.3) 14.8 (4.5)
N 5 37a
FBI-ALS 9.7 (9.9) 9.3 (9.1)
N 5 36a
Abbreviations: ALS-CBS 5 Amyotrophic Lateral Sclerosis-Cognitive Behavioral Screen;
CNS-LS 5 Center for Neurologic Study-Lability Scale; COWAT 5 Controlled Oral Word
Association Test; FBI-ALS 5 Frontal Behavioral Inventory-ALS; PLS 5 primary lateral scle-
rosis; SSEP 5 somatosensory evoked potential.
All data are mean (SD) unless otherwise indicated.
aNumber of patients with complete cognitive testing data.
b Percentages derived from the Written Verbal Fluency Index or the COWAT (consisting of 3
scores)—see the text for further explanation.
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ALS, and other known neurologic diseases. We iden-
tified one previously described pathogenic mutation
in the SPG7 gene in heterozygous form (A510V) in
patient 121 and one C9ORF72 expansion in patient
8.14 Patient 1 and patient 8 belong to the larger clus-
ter (figure 2). Patient 11 had a predicted pathogenic
heterozygous mutation in PARK2,22 and patient 41
had a predicted risk allele in DCTN1.23
Patient 11 also belonged to the larger cluster;
patient 41 was not clustered because cognitive testing
data were incomplete. A predicted pathogenic muta-
tion in the SYNE2 gene was identified in patient 6.24
However, there was no evidence of myopathy. Several
other patients showed SNPs of unknown significance
in the PARK2 (patient 23), VEGFA (patient 26),
CLN6 (patient 29), BTD (patient 29), and LRKK2
(patient 32) genes.
From our exome sequencing performed on all pa-
tients with PLS, we have identified a combined 4,500
rare (population frequency less than 1%) missense or
nonsense variants that occurred in at least 2 patients
with PLS. Among these 4,500 variants, one-third
mapped to genes with some disease-related annota-
tion in the Online Mendelian Inheritance in Man
database, and about one-third were predicted to dis-
rupt protein function based on functional prediction
algorithms (SIFT, Provean). We are currently refin-
ing our analysis and classification of these variants.
DISCUSSION Our overall goal was to take the first
step toward determining, through analyzing pheno-
types and genotypes, whether PLS is a single entity
or a syndrome including multiple neurodegenerative
variants. The expanding knowledge of genotypic
expression has made it clear that the traditional view
of the relationship between phenotypes and geno-
types is simplistic. Detailed phenotypic information
is now considered essential to understanding new or
poorly defined diseases, such as PLS. We accom-
plished our goal in 2 ways: first, by using k-means
clustering of phenotypic characteristics to identify
groups of similar patients, and second, by using
exome sequencing to identify possible genes associ-
ated with these phenotypes.
Our study has several strengths. We prospectively
enrolled only those patients with clinically “definite”
Figure 1 Within-groups sum of squares vs number of clusters
Within-groups sum of squares vs number of clusters to determine the number needed for
k-means cluster analysis. The cluster algorithm assumes a given number of clusters to deter-
mine the grouping of patients. Figure 1 shows 15 separate cluster algorithms with 1–15
clusters assumed and the within-groups sum of squares calculated for each. Optimally, one
would like to select a small number of clusters for ease of interpretation but with a small
within-groups sum of squares. When there is a bend (like an elbow), it provides evidence that
the gain is large (i.e., reducing the sum of squares) in identifying a fixed number of clusters
with decreased evidence to increase the number of clusters. Our analysis showed no evi-
dence of a bend, so we chose 2 clusters for convenience of interpretation.
Figure 2 Cluster dendrogram
Cluster dendrogram for similarity between patients with primary lateral sclerosis with complete datasets (N 5 25). Each
patient is denoted by a corresponding code number.
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PLS to narrow clinical diversity and sought to identify
any further possible subsets using phenotype cluster
analyses. Subsequent k-means clustering, combined
with a final model-building step, suggests that patients
with PLS may be classified into 2 groups based on the
presence or absence of the following clinical variables:
dysarthria, dysphagia, objective bulbar signs, urinary
urgency, weight loss, and sensory impairment. One
limitation of this approach, however, is that the Lasso
method chooses variables randomly from sets of highly
correlated variables; thus, the selected variables may
represent a subset of the entire group of variables.25
However, the results of sensitivity analyses were essen-
tially similar, and these put fewer restrictions on the
number of variables with complete data. Therefore,
our results suggest that the diagnosis of PLS may rep-
resent at least 2 different groups of patients.
Another important strength is genetic analysis of all
patients to test for the presence of known disease-
causing mutations associated with other neurodegener-
ative disorders. Mutations in SPG7 (A510V) result in
autosomal recessive spastic paraplegia. The mutation
found in patient 1 is a heterozygous SPG variant,
which is reported to predispose individuals to late-
onset, complex neurodegenerative disorders.26 A more
recent study indicates that this particular heterozygos-
ity can be pathogenic for HSP27 (personal communi-
cation with Dr. John Fink, University of Michigan,
June 2014). Patient 8 presented with clinically typical
PLS but was found to have C9ORF72 hexonucleotide
repeat expansion. A Dutch group previously described
a single patient with C9ORF72 expansion in a PLS
cohort of 110 patients.28 Although C9ORF72 expan-
sion is predominantly found in patients with ALS or
ALS plus frontotemporal dementia, it has been
described in other neurodegenerative diseases.28 Varia-
ble clinical phenotypes may be the result of complex
environmental interactions and genetic modifiers.29
Our study and the Dutch study indicate that
C9ORF72 expansion can be expressed phenotypically
as typical PLS.
Features of atypical Parkinson disease (PD) have
been reported in patients with a diagnosis of PLS.30,31
Although none of our patients had clinical features of
PD, we found mutations in the PARK2 gene
(Arg275Trp) previously described as a cause of familial
PD. This PARK2 gene mutation is pathogenic when
homozygous, but the heterozygous variants are re-
ported to affect PD onset32 and phenotype.33,34 The
LRRK2 mutation is known to cause autosomal domi-
nant familial PD, although in one study of large fam-
ilies the R1514Q mutation in our patient (patient 32)
had not segregated with PD.35 Yet other LRRK2 muta-
tions are found in sporadic PD cases,36 and typical MND
is reported in patients with familial PD resulting from a
different LRRK2 mutation.37 Although the LRRK2
mutation is interesting, its pathogenic significance in
our patient with PLS is at best uncertain, and thus we
consider it to be an SNP at this time. Our exome
sequencing also identified another important mutation
that is a known pathogenic mutation of the DCTN1
gene38; although this mutation is rare, it has been reported
in an apparent sporadic case of ALS.22
Therefore, exome sequencing identified 4 poten-
tially pathogenic mutations occurring in 34 patients
with PLS (nearly 12%), all associated with neurodegen-
erative diseases such as ALS, HSP, and PD. With
increasing knowledge in the near future, we may need
to consider genetic counseling for patients who are
found to have known gene mutations. Patients with 2
of these mutations belong to the cluster having the
larger number of patients. Five other SNPs of unknown
clinical significance were also detected (PARK2,
VEGFA, CNL6, BTD, and LRRK2) as well as a pre-
dicted pathogenic mutation in SYNE2. Based on our
experience, we recommend that patients with a diagno-
sis of PLS, especially those participating in research
studies, be screened for pathogenic mutations using
partial or complete exome sequencing to determine
the prevalence of known pathogenic mutations and
the pathogenic significance of variants of unknown sig-
nificance. Further studies are needed to clarify the sig-
nificance of these SNPs and the SYNE2 mutation.
The diagnosis of PLS is still problematic because of
the time required to wait before making a diagnosis
and how strictly pure UMN involvement is defined.
We decided to use very strict criteria (5 years after
symptom onset before enrollment) so we could inves-
tigate clinically well-defined PLS cases. Yet waiting for
such an extended time to make the diagnosis is neither
practical nor helpful because physicians need to make a
diagnosis at the earliest opportunity. Investigators also
want to start PLS research at earlier stages of the dis-
ease, when active biological changes can be more read-
ily found. We made every effort to select patients who
had a “definite” diagnosis of PLS, short of autopsy
proof. Therefore, disease diagnosed using our clinical
criteria as described above (pure UMN dysfunction
with normal EMG along with bulbar symptom(s),
normal neuroimaging, and all definable diseases
excluded) with negative exome sequencing and a neg-
ative C9ORF72 expansion test can be considered clin-
ically “definite” PLS for research purposes currently.
PLS with a shorter disease duration (3–4 years) could
be considered clinically “probable” or clinically “possi-
ble.” These clinically probable or possible cases could
be elevated to definite PLS if the exome sequence and
C9ORF72 expansion tests detect no known molecular
abnormalities. Until we have improved biological or
genetic markers, such criteria may be suitable for
research investigation of PLS. We need an updated
international consensus for PLS diagnosis.
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Study limitations. Although the number of patients we
studied is not small in comparison to other studies in
PLS, a larger number of patients is required to achieve
definitive results for both clinical clustering and exome
sequencing analyses. We need to include more centers,
preferably with long-term funding to allow adequate
time for recruitment and to overcome the limitations
involved with studying such a rare disease. Another
limitation is the selection of patients with clinically
“definite” PLS, which included patients who are in
more advanced stages of the disease. Waiting a long
period of time to diagnose PLS is a major drawback.
Ideally, we should study PLS much earlier in the disease
course, when biomarkers that can identify early PLS are
most essential. To find such biomarkers, studying
patients with clinically “definite” PLS is a necessary step.
We identified 2 phenotypic groups and a small
number of patients with gene mutations known to
be pathogenic for various neurodegenerative dis-
eases. Further studies are needed. Our study is only
the beginning of such investigations in PLS, provid-
ing a foundation that will hopefully stimulate other
investigators to examine and expand our phenotypic
and genetic studies in order to more fully under-
stand PLS.
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